Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Astellas Pharma Inc | 18 |
| 2 | Sucampo GmbH | 5 |
| 3 | Daiichi Sankyo Co Ltd | 3 |
| 4 | Emory University | 2 |
| 5 | Sankyo Co Ltd | 1 |
Where innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 25 |
| 2 | A61P | Therapeutic activity (drug indications) | 22 |
| 3 | C07D | Heterocyclic compounds | 8 |
| 4 | Y02P | Climate change mitigation: production | 5 |
| 5 | C07F | Organometallic compounds | 4 |
| 6 | C07H | Sugars and derivatives | 3 |
| 7 | A61L | Sterilising / disinfecting materials | 2 |
| 8 | B01D | 2 | |
| 9 | B01J | Chemical/physical processes (e.g. catalysts) | 2 |
| 10 | C07C | Acyclic and carbocyclic compounds | 2 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Renal Transplantation Outcomes and Treatments | 111 |
| 2 | Signaling Pathways in Disease | 75 |
| 3 | Dermatology and Skin Diseases | 24 |
| 4 | Organ Transplantation Techniques and Outcomes | 24 |
| 5 | Transplantation: Methods and Outcomes | 15 |
| 6 | Pancreatic function and diabetes | 11 |
| 7 | Neurological Complications and Syndromes | 10 |
| 8 | Renal Diseases and Glomerulopathies | 8 |
| 9 | Drug Transport and Resistance Mechanisms | 7 |
| 10 | melanin and skin pigmentation | 7 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | John J. Fung | University of Pittsburgh | 283 |
| 2 | Thomas E. Starzl | University of Pittsburgh | 271 |
| 3 | Satoru Todo | University of Pittsburgh | 88 |
| 4 | Ron Shapiro | University of Pittsburgh | 86 |
| 5 | P. Neuhaus | Humboldt-Universität zu Berlin | 79 |
| 6 | Andreas G. Tzakis | University of Miami | 74 |
| 7 | Dirk Kuypers | KU Leuven | 59 |
| 8 | Raman Venkataramanan | University of Pittsburgh | 55 |
| 9 | Anthony J. Demetris | University of Pittsburgh | 50 |
| 10 | Lionel Rostaing | Hôpital Rangueil | 48 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen | 2000 | 5275 | Renal Transplantation Outcomes and Treatments |
| Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes | 1991 | 4154 | Signaling Pathways in Disease |
| Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders | 2011 | 3664 | Telomeres, Telomerase, and Senescence |
| Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model | 2007 | 2291 | Neuroscience and Neuropharmacology Research |
| The mechanism of action of cyclosporin A and FK506 | 1992 | 2149 | Viral Infections and Immunology Research |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Prograf?
Which organizations hold the most patents for Prograf?
What are the primary research topics associated with Prograf studies?
Who are the most prolific authors publishing research on Prograf?
What is the current patent and publication activity for Prograf?